Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alexandria Venture Investments
BioCentury | Dec 12, 2024
Deals
Nvelop, Chroma merger creates opportunity for targeted epigenome editors
Nvelop CEO Jeff Walsh will lead nChroma, which has $75M in new funding and a lead for HBV
BioCentury | Nov 15, 2024
Emerging Company Profile
Archon: Tuning antibodies through geometry
Latest spinout from David Baker’s IPD rescuing failed mAbs by forcing them into cage-like structures for better biodistribution, target engagement
BioCentury | Oct 8, 2024
Emerging Company Profile
Judo Bio: Making the kidney the access point for siRNA therapies
New Cambridge, Mass., biotech is delivering oligonucleotides to the kidneys to treat systemic and renal diseases
BioCentury | Sep 26, 2024
Finance
Eyes on Europe: Asabys’ €180M fund, Genespire’s record series B
BioCentury’s weekly Venture Report also includes Arch’s latest fund, Flagship-backed Mirai, series Bs for Vicebio and 858, and more
BioCentury | Sep 12, 2024
Finance
Venture Report: Big rounds for Candid, Superluminal, PanTera
Plus: Rounds for Radiant, Vironexis, Bambusa, OrsoBio and F2G
BioCentury | Sep 5, 2024
Discovery & Translation
AI for target discovery: the start of a long road
Back to School 2024: Investments in AI in drug discovery pick up, as the picture starts to form of how target discovery may benefit
BioCentury | Aug 1, 2024
Finance
Venture Report: venBio closes new $528M fifth fund
Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers
BioCentury | Jul 29, 2024
Deals
Deals Report: GSK is latest pharma to draw on Flagship portfolio
Plus: Day One’s ex-U.S. deal with Ipsen; Novartis taps Dren Bio’s oncology platform; BI buys Avalon-backed Nerio; and Collegium’s ADHD takeout
BioCentury | Jul 18, 2024
Emerging Company Profile
Clasp: Optimizing T cell engagers for tighter binding, more cancer killing
Launched in March with $150M, Clasp is designing T cell-engaging bispecifics to better fit the immune synapse
BioCentury | Jun 21, 2024
Finance
Venture Report: Syncona’s backs a pair of biotechs; Marea makes debut with $190M
Plus: Forbion’s new sustainability fund, and rounds for Elion, ashibio, NephroDI and Ability
Items per page:
1 - 10 of 384